Neodyne Biosciences, Inc

Neodyne Biosciences is deeply dedicated to skin health. The future of medical devices demands skin and site health. Through cutting-edge research and development, we have created groundbreaking solutions that enhance the effectiveness of devices and optimize overall skin health. Created at Stanford University, we are led by an experienced team of medical device industry executives.  We start with science and go below the surface of the skin to create solutions that deliver above and beyond. A leader at the forefront of scar prevention, our unique patch technology — embrace® Active Scar Defense is a patented scar prevention solution. Proven to significantly decrease scarring in two randomized control studies, it's the only 510 (K) cleared medical device of its kind on the market backed by clinical data that minimizes scarring and fibrosis. embrace® uses mechanical tension off-loading to minimize scarring and fibrosis. This proprietary, state-of-the-art, compression mechanism of action reduces inflammation, excessive fibrosis and collagen proliferation, which helps prevent scar tissue formation and aids in remodeling damaged tissue. After successfully establishing our technology as a global standard of care for the prevention of scarring, we set our sights on microtrauma events. Skin integrity is critical by people with diabetes who currently experience ongoing skin microtrauma caused by continuous glucose monitors and continuous subcutaneous insulin infusion pumps as well as repeated injections.   Our current clinical trials focus on the treatment and prevention of Lipohypertrophy (LH) in diabetes patients. LH is proven to impair insulin absorption and impede effective diabetes management. Currently, no medical technology or solutions exists. We are leading the way in scar prevention and healing across acute and chronic indications. [email protected]

• Employees 15
• Founded 2007
• Annual Revenue $8000000